Evidence map›Paper›PMID 40950285›Full record

ArticleAmerican journal of translational research2025

Clinical characteristics of primary pulmonary hemangiosarcoma outcomes: a Surveillance, Epidemiology, and End Results database analysis.

Jia-Chun Sun, Zi-Han Yang, Hao-Lin Shi, Ting-Ting Wei, Bo Sun, Jing-Xiang Su, Hong-Yan Liu, Qing-Feng Wang, Xin-Yang Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jia-Chun SunHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology Luoyang 471003, Henan, China.
Zi-Han YangHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology Luoyang 471003, Henan, China.
Hao-Lin ShiHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology Luoyang 471003, Henan, China.
Ting-Ting WeiHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology Luoyang 471003, Henan, China.
Bo SunSchool of Basic Medical Sciences, Henan University of Science and Technology Luoyang 471023, Henan, China.
Jing-Xiang SuHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology Luoyang 471003, Henan, China.
Hong-Yan LiuHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology Luoyang 471003, Henan, China.
Qing-Feng WangHenan Provincial Luoyang Orthopedics Hospital (Henan Provincial Orthopedics Hospital) Luoyang 471023, Henan, China.
Xin-Yang LiHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology Luoyang 471003, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary pulmonary hemangiosarcoma (PPHS) is an extraordinarily rare disorder. The objective of this study was to investigate the demographic characteristics and prognostic factors of patients with PPHS. Patients diagnosed with PPHS between 2000 and 2020 based on data from the Surveillance, Epidemiology, and End Results (SEER) database were retrospectively analyzed. Survival analysis was performed using the survival package of R (4.2.0). Univariate and multivariate Cox proportional hazards models were used to analyze independent prognostic factors. A nomogram was constructed by the R Regression Modeling Strategies (rms) package. A total of 123 patients with PPHS were included in this study; their mean survival time was 13.8 months. Further investigation revealed that the disease-specific survival rates of patients with PPHS at 1, 2, 3, and 5 years were 20.17%, 14.29%, 10.08%, and 5.88% respectively. In the regression analysis, age, tumor status, and treatment were identified as risk factors for patients with PPHS. In addition, chemotherapy was crucial for the treatment of patients with PPHS (P < 0.05). Finally, the nomogram we constructed to predict 0.5-, 1-, 2-, and 3-year disease-specific survival in patients with PPHS showed good accuracy (concordance index: 0.769). Age, tumor laterality, and tumor size were independent factors affecting the prognosis of patients with PPHS, and chemotherapy may significantly improve the long-term prognosis.

Indexed as

chemotherapyPrimary pulmonary hemangiosarcomaprognostic factors

Identifiers

PMID40950285
PMCPMC12432692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.